AXSMAxsome Therapeutics, Inc.

$8B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$21M

Net Income

-$23M

EPS (Diluted)

$-0.61

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$16M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$204M

Total Liabilities

$68M

Stockholders' Equity

$135M

Cash & Equivalents

$202M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$21M	-$19M	-11.5%
Net Income	-$23M	-$19M	-19.8%

AXSM Q3 2020 Earnings — Axsome Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena